Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Idorsia
Biotech
Nxera sells lupus drug's APAC rights to Viatris for $10M upfront
Nxera Pharma has sold the Asia-Pacific rights to its phase 3 autoimmune drug to Viatris for $10 million upfront.
James Waldron
Feb 28, 2025 5:10am
With no Tryvio buyer, Idorsia recoups $100M from Viatris deal
Feb 26, 2025 7:00am
Idorsia's Tryvio sale behind schedule, but layoffs on track
Dec 20, 2024 4:42am
Idorsia teases Tryvio licensing deal while planning 270 layoffs
Nov 27, 2024 4:15am
Neurocrine, Idorsia part ways 2 years after double phase 2 fails
Oct 29, 2024 7:15am
Idorsia bags $350M upfront from Viatris for 2 late-phase assets
Feb 28, 2024 7:56am
